What the PCAC is — and what it is not

The Pharmacy Compounding Advisory Committee is an FDA advisory body composed of physicians, pharmacists, research scientists, and patient advocates who are not FDA employees. Advisory committees exist throughout FDA’s structure to provide outside expert input on complex scientific and policy questions. Their opinions are exactly that: opinions. The FDA is not legally bound by PCAC recommendations in any direction. The agency can accept a favorable vote, reject it, partially accept it, or choose not to act on it at all. In practice, the FDA follows PCAC recommendations more often than not — but the vote itself creates no legal obligation and changes no regulatory status for any compound on the day it is taken. BPC-157 was not approved for compounding on July 23. It was not reclassified. The only thing that changed on July 23 was that the PCAC’s formal position was recorded in favour of placing BPC-157 on the 503A Bulk Drug Substances List, and the FDA now has a procedural basis to initiate rulemaking if it chooses to do so.

This distinction matters because the research community has a documented tendency to conflate advisory votes with regulatory approvals — a pattern that recurs with drug approval advisory panels, food additive reviews, and compounding advisory hearings alike. The confusion is understandable: when a committee composed of experts votes in favour of something by a meaningful margin, it carries the intuitive weight of a decision. Legally, it does not. The formal process that converts a PCAC recommendation into an actual change in compounding law is the Federal Register rulemaking process, and that process has several distinct stages, each of which takes time.

Step one: the FDA reviews the PCAC recommendation

After the PCAC votes, the FDA’s Office of Pharmaceutical Quality and its compounding policy team review the advisory committee record — the transcripts, submitted public comments, the PCAC members’ stated reasoning, and the FDA staff briefing documents that preceded the hearing. This internal review is not a rubber stamp. The agency can and does decline to follow advisory committee recommendations when it concludes that the committee weighed evidence differently than the statutory standard requires. In the case of the July 2026 PCAC hearing, this review is complicated by the fact that the committee voted in direct opposition to the FDA staff recommendation on six of seven compounds. That is not unprecedented — advisory panels override staff recommendations regularly — but it does mean the agency’s internal review will need to engage seriously with the committee’s reasoning and reconcile it with the staff’s analysis. This review phase does not have a fixed statutory deadline. Based on historical patterns with compounding advisory committee actions, it typically runs between two and six months from the date of the hearing.

Step two: the proposed rule in the Federal Register

If the FDA decides to follow the PCAC recommendation — or some version of it — the next step is publication of a proposed rule in the Federal Register. This is the formal mechanism by which the federal government announces its intention to change a regulation and invites public participation in the process. The proposed rule for 503A Bulk Drug Substances additions describes the specific compound or compounds being considered, the criteria applied, the evidence the FDA reviewed, and the proposed regulatory text that would result if the rule is finalised. The 2016 addition of bulk drug substances to the 503A list followed this exact process: proposed rule publication, comment period, review, final rule.

The proposed rule triggers a mandatory public comment period, which under the Administrative Procedure Act is typically 60 days but can be extended. Anyone — compounders, patient advocacy organisations, physicians, researchers, pharmaceutical manufacturers, or members of the public — can submit written comments to the docket. The FDA is required to read and formally respond to all substantive comments in the final rule. If the agency receives thousands of comments on a complex scientific question (as it did with the GLP-1 503B exclusion proposal, which generated 3,901 comments before the July 30 deadline), working through them takes considerable time and resources. For a compound like BPC-157, which has a large and engaged patient and research community, the comment volume could be substantial. Comments do influence outcomes: if a large number of well-reasoned comments identify a flaw in the FDA’s analysis or evidence base, the agency may modify or delay the final rule in response.

Step three: the comment review and final rule

After the comment period closes, the FDA’s regulatory staff reads every substantive submission, categorises them by issue, drafts responses to each category, and incorporates those responses into the final rule document. This is the most time-consuming phase of the rulemaking process, and it is the phase most susceptible to resource constraints, competing priorities, and political disruption. The FDA operates across dozens of simultaneous rulemaking proceedings at any given time; a new administration can shift priorities; litigation can pause or redirect a rulemaking; Congress can intervene. The GLP-1 503B exclusion proposal — which affects semaglutide, tirzepatide, and liraglutide — is expected to produce a final rule within six to twelve months of its July 30, 2026 comment deadline. Compounding access rulemaking for 503A Bulk Drug Substances has historically moved more slowly, because the substantive scientific questions are more contested and the economic stakes for the compounding industry are lower than for the branded pharmaceutical industry that opposed GLP-1 compounding.

The final rule, once published, establishes the binding regulatory change. At that point — and not before — licensed 503A compounding pharmacies may legally include BPC-157, TB-500, or whichever other compounds the final rule addresses on the Bulk Drug Substances List and may compound them for individual patients under valid prescriptions from licensed practitioners. The final rule typically includes an effective date — commonly thirty to sixty days after publication — before which the change does not apply even if the rule is already published.

The realistic timeline: 12 to 24 months from the PCAC vote

Working through the phases described above — FDA internal review, proposed rule drafting and publication, comment period, comment review, final rule publication — the historical range for 503A compounding rulemaking is twelve to twenty-four months from the PCAC vote, under conditions where the FDA proceeds without significant delays. That means the earliest plausible date for legal 503A compounding of BPC-157 or TB-500, assuming the FDA promptly initiates rulemaking following the July 2026 vote, is mid to late 2027. A more cautious estimate puts it at 2028, particularly if the comment period generates a high volume of substantive submissions that require extended review. Researchers and clinicians asking “when will I be able to get BPC-157 from a licensed compounding pharmacy?” should plan around a 2027–2028 window, not the coming months.

It is also worth noting that even after final rulemaking, 503A access is not equivalent to open-market availability. The 503A pathway requires a patient-specific prescription from a licensed prescriber, pharmacy preparation within FDA-registered state-licensed compounding facilities, and no commercially available alternative. It does not create a direct-to-consumer research chemical market or permit the sale of BPC-157 without prescriber involvement. The grey-market vendor model — where compounds are sold as research chemicals without prescriptions — operates outside the 503A framework entirely and is not affected by 503A rulemaking in either direction. DSIP (Emideltide), the sole compound rejected by the PCAC in a 6–7 vote, will not proceed to rulemaking for 503A listing based on the July vote. It remains in its current regulatory position: removed from the Category 2 “do not compound” list in April 2026 but without a positive path toward formal 503A authorisation at this time.

What could delay or derail the rulemaking

Several factors could extend the timeline beyond the 12–24 month baseline. Congressional action — either accelerating deregulation under the MAHA agenda or imposing additional scrutiny — could redirect the rulemaking. Litigation is a real possibility: branded pharmaceutical manufacturers or patient safety organisations could challenge the rulemaking at the proposed or final rule stage, potentially triggering judicial review that pauses the effective date. A change in FDA leadership priorities — which can occur with any administration transition or senior staff turnover — can slow a rulemaking that is politically sensitive. The manufacturing quality standards that must accompany the final rule are themselves technically complex: the FDA will need to specify the allowable impurity profile, stability testing requirements, and container closure specifications for a synthetically produced tetrapeptide like BPC-157, and reaching those specifications in a way that small-scale compounders can practicably meet takes time to draft and finalise.

The most straightforward path to delay is simply volume and workload. The FDA is simultaneously managing the GLP-1 503B rulemaking, the Seventh Circuit oral argument on retatrutide’s biologic classification (scheduled September 24, 2026), the ongoing tirzepatide cardiovascular label expansion review, and its standard pharmaceutical approval pipeline. Compounding policy rulemaking competes for staff time and leadership attention against programmes that generate far more revenue and political visibility. This is not speculation about bad faith — it is a structural feature of how regulatory agencies prioritise work, and it is the primary reason rulemaking timelines routinely exceed initial estimates.

What researchers and clinicians can do now

The PCAC vote is genuinely meaningful as a signal of regulatory direction, and it provides a legitimate basis for optimism that legal 503A access to BPC-157 and TB-500 will eventually arrive. In the interim, the practical options have not changed. Researchers operating within institutional frameworks can access these compounds through licensed research channels. Clinicians interested in peptide-based therapeutic approaches can work with regulatory counsel to evaluate whether any current 503A pathway exceptions apply to their specific patient population and clinical context. The public docket for the 503A rulemaking, once it opens, will be an opportunity for researchers and clinicians to submit substantive comments that can directly influence how the FDA drafts the final rule, including the specification standards and allowable clinical indications.

What has changed is the direction of travel. Two years ago, BPC-157 was explicitly prohibited from compounding. Thirteen months ago, it was removed from Category 2 but without any affirmative pathway forward. Today there is a positive PCAC recommendation on the record, a formal rulemaking process to initiate, and a regulatory environment that is more favourable to peptide compounding access than at any point in the last decade. The road is long and the timeline is measured in years, not months — but for the first time, there is a road. Peptide Hub will continue tracking each stage of the rulemaking process and updating the relevant database entries as formal developments occur. The current regulatory status for each affected compound is maintained in the dosing guide and individual database entries.

---

Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.

Sources

1. FDA — July 23–24, 2026 PCAC meeting calendar and briefing documents: fda.gov
2. ABC News — FDA advisory committee votes to add BPC-157 to compounding list (July 23, 2026): abcnews.go.com
3. NPR — Advisers to the FDA vote to ease regulation of popular peptides (July 23, 2026): npr.org
4. RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list (July 24, 2026): raps.org
5. Federal Register — Bulk Drug Substances Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act: federalregister.gov
6. FDA — Section 503A of the FD&C Act and compounding pharmacy overview: fda.gov
7. Orrick — FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings (April 2026): orrick.com
8. MarketWatch — Most FDA advisers say peptides like BPC-157 and TB-500 should be available (July 2026): marketwatch.com